Suppr超能文献

多糖和低聚糖的消化与人体肠道微生物发酵。

digestion and human gut microbiota fermentation of polysaccharides and oligosaccharides.

机构信息

College of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, China.

出版信息

Front Cell Infect Microbiol. 2023 Feb 1;13:1105335. doi: 10.3389/fcimb.2023.1105335. eCollection 2023.

Abstract

BACKGROUND

is one of the commonly used traditional Chinese medicine. polysaccharides (BP) and oligosaccharides (BO) are one of the main components of , which have been proved to have a variety of biological activities. However, the digestion and fermentation characteristics of BP and BO are still unclear.

METHODS

The study evaluated different prebiotic effects of BP and BO by simulating digestion and gut microbiota fermentation.

RESULTS

The results show that the simulating saliva partly degraded BP, but had no effect on BO. The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion. In addition, BP and BO could be rapidly degraded and utilized by gut microbiota. During fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly. Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group. Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of and , and the downregulated populations of Escherichia and Bacteroides. There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups. The fermentation broth of the BP group displayed a stronger suppression of O-, but a higher scavenging effect on DPPH for the BO group.

CONCLUSIONS

BP and BO displayed different digestion and fermentation characteristics due to their distinct polymerization degrees. The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.

摘要

背景

是一种常用的中药。多糖(BP)和低聚糖(BO)是 的主要成分之一,已被证明具有多种生物活性。然而,BP 和 BO 的消化和发酵特性尚不清楚。

方法

本研究通过模拟消化和肠道微生物发酵来评估 BP 和 BO 的不同益生元作用。

结果

结果表明,模拟唾液部分降解了 BP,但对 BO 没有影响。BP 和 BO 的分子量在胃和肠道消化过程中基本保持不变。此外,BP 和 BO 可被肠道微生物快速降解和利用。在发酵过程中,BP 和 BO 组的生长速度高于对照组,BP 组和 BO 组的 pH 值和总碳水化合物含量显著降低。虽然 BO 组的还原糖水平迅速下降,但在 BP 组中仍保持在较低水平。BP 和 BO 均改善了肠道微生物群落的组成和结构,表明 和 的丰度上调,而 Escherichia 和 Bacteroides 的丰度下调。BP 和 BO 组肠道微生物产生的 SCFA 和抗氧化活性存在差异。BP 组发酵液对 O-的抑制作用更强,而 BO 组对 DPPH 的清除作用更强。

结论

由于聚合度的不同,BP 和 BO 表现出不同的消化和发酵特性。该研究表明,BP 和 BO 未来可能通过选择性调节肠道微生物群,作为益生菌应用于人类疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ae/9929950/b0ed9a8f7af1/fcimb-13-1105335-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验